Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2014-12-01 Major Shareholding Noti…
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
PR_THR 281114 transparantie.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled 'PERSBERICHT' (Press Release) and details the receipt of a 'transparantiemelding' (transparency notification) regarding a change in significant shareholding by Norges Bank, falling below a threshold (2.80%). It then lists other major shareholders and their stakes. This content directly relates to notifications about changes in significant share ownership, which corresponds to the Major Shareholding Notification category (MRQ). Although it is a press release, the core subject matter is the shareholding disclosure, making MRQ more specific than a general RPA or RNS. The document length is short (2990 chars), but the content is the disclosure itself, not just an announcement that a disclosure exists.
2014-12-01 Dutch
BR-#9663603-v2-Thrombogenics_-_EGM_2_re_issuance_warrants_-_Shareholder_rights_(ENG)_0.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document explicitly discusses the rights of shareholders to ask questions in writing before an extraordinary general shareholders' meeting scheduled for December 4, 2014. It details the conditions for exercising this right (registration date, intent to participate) and the deadline for submitting questions. This content directly relates to the procedures and information provided to shareholders in preparation for a general meeting, which aligns with the purpose of a Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. Although it mentions the meeting, it is focused on the procedural rights of shareholders regarding questions, which is a key component of proxy materials, rather than the final voting results (DVA) or the meeting presentation itself (AGM-R). Given the focus on shareholder rights and pre-meeting procedures, PSI is the most appropriate classification.
2014-11-17 English
BR-#9611751-v3-Thrombogenics_-_Convening_Notice_EGM_2-_Issuance_of_Warrants_-_ENG_0.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Convocation of the Extraordinary General Shareholders' Meeting' for ThromboGenics. It outlines the agenda, proposed resolutions (specifically regarding a warrant plan and capital increase), and instructions for shareholder participation, voting, and proxy submission. This document is a classic proxy solicitation and information statement provided to shareholders to inform them of an upcoming meeting and request their participation/votes.
2014-11-17 English
BR-#9663533-v2-Thrombogenics_-_Proxy_EGM_2_Issuance_of_warrants_(DUTENG).pdf
AGM Information Classification · 98% confidence The document is explicitly titled 'VOLMACHT' (Proxy) and 'PROXY' in the English translation. It is a form granting authority to a representative to vote on behalf of a shareholder at an 'extraordinary general shareholders' meeting' (buitengewone algemene vergadering). This material is directly related to soliciting shareholder votes and providing information for that purpose, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it discusses agenda items that might appear in an AGM, the document itself is the mechanism for proxy voting, not the final AGM results (DVA) or the general AGM presentation materials (AGM-R).
2014-11-17 Dutch
BR-#9663664-v1-Thrombogenics_-_EGM_2_2014_-_letter_re_convening_notice_-_ENG.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is an invitation to a second extraordinary general shareholders' meeting (EGM) scheduled for December 4, 2014, because the first meeting failed to meet quorum. The agenda details proposals regarding a new warrant plan (Warrant Plan 2014), cancellation of preferential subscription rights, and deviations from Belgian Company Code (BCC) articles related to remuneration. It also outlines admission requirements, voting procedures, and proxy instructions for the meeting. This content is characteristic of materials sent to shareholders to inform them about and solicit their votes for a general meeting. This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the final voting results (DVA), nor is it the full Annual Report (10-K) or a general Earnings Release (ER).
2014-11-17 English
PR_THR transparantieverklaring 171114 TC_LC final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled 'PERSBERICHT' (Press Release) and discusses the receipt of 'transparantiemeldingen' (transparency notifications) regarding significant shareholdings by Mr. Thomas M. Clay and Mr. Landon T. Clay, detailing the number of shares and percentage of outstanding shares held as of November 17, 2014. This directly relates to changes in significant share ownership levels, which aligns perfectly with the definition for Major Shareholding Notification (MRQ). Although it is a press release, the core content is the notification of ownership change, not just an announcement of a report release (RPA) or a general regulatory filing (RNS).
2014-11-17 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.